10月15日，兴齐眼药盘中上涨2.03%，截至10:18，报67.00元/股，成交1.85亿元，换手率1.48%，总市值 164.38亿元。 资金流向方面，主力资金净流入932.08万元，特大单买入758.51万元，占比4.11%，卖出698.28万元，占 比3.78%；大单买入4242.49万元，占比22.98%，卖出3370.64万元，占比18.25%。 兴齐眼药今年以来股价涨38.35%，近5个交易日涨1.93%，近20日跌5.71%，近60日涨25.61%。 截至6月30日，兴齐眼药股东户数4.63万，较上期增加8.71%；人均流通股4066股，较上期增加28.79%。 2025年1月-6月，兴齐眼药实现营业收入11.63亿元，同比增长30.38%；归母净利润3.35亿元，同比增长 97.75%。 分红方面，兴齐眼药A股上市后累计派现11.66亿元。近三年，累计派现9.85亿元。 机构持仓方面，截止2025年6月30日，兴齐眼药十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股349.80万股，相比上期增加96.80万股。南方中证500ETF（510500）位居第四大流通股 东，持股251 ...

资料显示，迈威(上海)生物科技股份有限公司位于中国(上海)自由贸易试验区蔡伦路230号2幢105室香港 铜锣湾希慎道33号利园1期19楼1928室，成立日期2017年5月12日，上市日期2022年1月18日，公司主营 业务涉及治疗用生物制品的研发、生产与销售。主营业务收入构成为：销售商品99.91%，提供劳务 0.09%。 10月15日，迈威生物盘中上涨2.05%，截至10:03，报45.33元/股，成交1.10亿元，换手率1.20%，总市值 181.14亿元。 资金流向方面，主力资金净流入607.26万元，特大单买入613.51万元，占比5.57%，卖出235.49万元，占 比2.14%；大单买入3098.47万元，占比28.13%，卖出2869.24万元，占比26.05%。 迈威生物今年以来股价涨124.41%，近5个交易日跌7.72%，近20日跌9.74%，近60日涨46.94%。 今年以来迈威生物已经5次登上龙虎榜，最近一次登上龙虎榜为9月2日。 迈威生物所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：AI医药、抗癌治癌、抗 癌药物、眼科概念、创新药等。 截至6月30日，迈威生物股东户 ...

Core Viewpoint - Aier Eye Hospital's stock has shown fluctuations, with a recent increase of 2.08% and a current price of 12.78 CNY per share, while the company has experienced a year-to-date decline of 2.38% [1] Financial Performance - For the first half of 2025, Aier Eye Hospital reported a revenue of 11.507 billion CNY, representing a year-on-year growth of 9.12%, and a net profit attributable to shareholders of 2.051 billion CNY, with a slight increase of 0.05% [2] - Cumulative cash dividends since Aier Eye Hospital's A-share listing amount to 7.12 billion CNY, with 3.6 billion CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders decreased to 343,900, while the average circulating shares per person increased to 23,064 [2] - The top ten circulating shareholders include significant entities such as Hong Kong Central Clearing Limited and various ETFs, with notable changes in their holdings [3] Market Activity - The stock's trading volume reached 790 million CNY with a turnover rate of 0.79%, indicating active market participation [1] - The net inflow of main funds was 56.118 million CNY, with large orders contributing significantly to both buying and selling activities [1] Business Overview - Aier Eye Hospital, established on January 24, 2003, specializes in various ophthalmic medical services, with its revenue composition including refractive projects (40.13%), vision services (23.64%), and cataract projects (15.48%) [1] - The company operates within the pharmaceutical and biological industry, specifically in the medical services sector, and is involved in several concept sectors such as medical aesthetics and smart healthcare [1]

Core Viewpoint - Dr. Optical's stock has experienced a significant decline this year, with a year-to-date drop of 22.22%, indicating potential challenges in the retail optical market [1][2]. Financial Performance - For the first half of 2025, Dr. Optical achieved a revenue of 686 million yuan, representing a year-on-year growth of 14.22%, while the net profit attributable to shareholders was 56.03 million yuan, up 6.97% year-on-year [2]. - The company has distributed a total of 464 million yuan in dividends since its A-share listing, with 204 million yuan distributed over the past three years [3]. Stock Market Activity - As of October 14, Dr. Optical's stock price was 29.73 yuan per share, with a market capitalization of 6.774 billion yuan. The stock has seen a trading volume of 150 million yuan and a turnover rate of 3.20% [1]. - The stock has appeared on the "龙虎榜" (a list of stocks with significant trading activity) twice this year, with the most recent instance on February 21, where it recorded a net buy of -235 million yuan [1]. Shareholder Information - As of June 30, the number of shareholders for Dr. Optical increased to 53,800, a rise of 9.25% from the previous period, with an average of 2,892 circulating shares per shareholder, up 19.81% [2]. - Notable new institutional shareholders include Guangfa Innovation Upgrade Mixed Fund and Minsheng Jia Yin Continuous Growth Mixed Fund, which are now among the top ten circulating shareholders [3]. Business Overview - Dr. Optical, established on April 23, 1997, and listed on March 15, 2017, primarily engages in optical retail, with its revenue composition being 68.65% from optical glasses and fitting services, 19.47% from finished lens products, and 10.80% from contact lens products [1].

Core Viewpoint - Yuyue Medical's stock has shown a modest increase of 2.01% on October 14, with a current price of 38.51 CNY per share and a total market capitalization of 38.605 billion CNY [1] Financial Performance - For the first half of 2025, Yuyue Medical reported a revenue of 4.659 billion CNY, representing a year-on-year growth of 8.16%, and a net profit attributable to shareholders of 1.203 billion CNY, which is a 7.37% increase compared to the previous year [2] Shareholder Information - As of September 30, Yuyue Medical had 50,000 shareholders, with an average of 18,803 circulating shares per person, showing no change from the previous period [2] - The company has distributed a total of 4.415 billion CNY in dividends since its A-share listing, with 2.402 billion CNY distributed in the last three years [3] Stock Trading Activity - On October 14, the net inflow of main funds was 11.4959 million CNY, with significant buying and selling activity noted [1] - The stock has experienced a year-to-date increase of 7.30%, with a slight decline of 3.24% over the past 20 days [1] Business Segmentation - Yuyue Medical's main business segments include respiratory treatment solutions (35.93%), clinical instruments and rehabilitation solutions (24.35%), home health monitoring solutions (21.77%), blood glucose management and POCT solutions (14.48%), and emergency solutions (2.92%) [1]

10月14日，京新药业盘中下跌2.03%，截至11:05，报18.86元/股，成交1.11亿元，换手率0.80%，总市值 162.39亿元。 分红方面，京新药业A股上市后累计派现21.10亿元。近三年，累计派现8.01亿元。 机构持仓方面，截止2025年6月30日，京新药业十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股964.92万股，相比上期减少1539.17万股。创新药（159992）退出十大流通股东之列。 资金流向方面，主力资金净流出828.41万元，特大单买入221.48万元，占比1.99%，卖出1419.61万元， 占比12.73%；大单买入2024.16万元，占比18.16%，卖出1654.44万元，占比14.84%。 责任编辑：小浪快报 京新药业今年以来股价涨51.26%，近5个交易日跌4.07%，近20日跌7.41%，近60日涨21.99%。 资料显示，浙江京新药业股份有限公司位于浙江省新昌县羽林街道新昌大道东路800号，成立日期1999 年2月13日，上市日期2004年7月15日，公司主营业务涉及化学制剂、传统中药、生物制剂、化学原料 药、医疗器械的研发、生产及销售。主营业务 ...

10月13日，京新药业盘中下跌2.04%，截至11:20，报19.24元/股，成交1.56亿元，换手率1.11%，总市值 165.66亿元。 京新药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：眼科概念、仿制药、抗 癌治癌、增持回购、融资融券等。 截至6月30日，京新药业股东户数2.57万，较上期减少0.11%；人均流通股28196股，较上期增加0.11%。 2025年1月-6月，京新药业实现营业收入20.17亿元，同比减少6.20%；归母净利润3.88亿元，同比减少 3.54%。 分红方面，京新药业A股上市后累计派现21.10亿元。近三年，累计派现8.01亿元。 机构持仓方面，截止2025年6月30日，京新药业十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股964.92万股，相比上期减少1539.17万股。创新药（159992）退出十大流通股东之列。 责任编辑：小浪快报 资金流向方面，主力资金净流出452.89万元，特大单买入102.38万元，占比0.65%，卖出474.29万元，占 比3.03%；大单买入2557.59万元，占比16.35%，卖出2638.58万元，占比1 ...

Core Insights - The stock price of Maiwei Bio has increased by 129.75% year-to-date but has recently experienced a decline of 9.36% over the past five trading days and 14.40% over the past 20 days [2] - The company reported a revenue of 1.01 billion yuan for the first half of 2025, a year-on-year decrease of 12.43%, and a net profit attributable to shareholders of -5.51 billion yuan, down 23.90% year-on-year [2] Company Overview - Maiwei Bio, established on May 12, 2017, and listed on January 18, 2022, is located in the Shanghai Free Trade Zone and specializes in the research, production, and sales of therapeutic biological products [2] - The company's main revenue source is from product sales, accounting for 99.91%, with service provision making up 0.09% [2] - Maiwei Bio operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in concepts such as AI medicine, ophthalmology, and innovative drugs [2] Shareholder and Institutional Holdings - As of June 30, 2025, the number of shareholders for Maiwei Bio increased by 11.66% to 17,900, with an average of 11,379 circulating shares per shareholder, a decrease of 10.44% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder with 4.74 million shares, and new entrants such as Xingquan Helun Mixed A and Penghua Medical Technology Stock A [3] - Several funds, including HSBC Jintrust, have exited the top ten circulating shareholders list [3]

Company Overview - Jiangsu Hengrui Medicine Co., Ltd. is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology and covering various research areas including kinase inhibitors, antibody-drug conjugates (ADC), tumor immunology, hormone receptor regulation, DNA repair, and supportive therapies [2] - The company's product portfolio includes anti-tumor drugs, analgesics, and contrast agents, applicable in various fields such as autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory diseases, hematological diseases, pain management, neurological diseases, ophthalmology, and nephrology [2] - The main revenue composition is as follows: oncology 52.12%, neuroscience 15.33%, others (supplementary) 10.63%, contrast agents 9.82%, metabolic and cardiovascular 6.25%, others 3.07%, immunology and respiratory system 2.78% [2] Financial Performance - As of June 30, 2025, Hengrui Medicine achieved a revenue of 15.76 billion yuan, representing a year-on-year growth of 15.88%, and a net profit attributable to shareholders of 4.45 billion yuan, with a year-on-year increase of 29.67% [3] - The company has distributed a total of 9.30 billion yuan in dividends since its A-share listing, with 3.57 billion yuan distributed over the past three years [3] Stock Performance - On September 30, Hengrui Medicine's stock price increased by 2.11%, reaching 70.66 yuan per share, with a trading volume of 1.846 billion yuan and a turnover rate of 0.41%, resulting in a total market capitalization of 468.985 billion yuan [1] - Year-to-date, the stock price has risen by 54.62%, with a 1.38% increase over the last five trading days, a 2.60% increase over the last twenty days, and a 32.32% increase over the last sixty days [1] - The net inflow of main funds was 169 million yuan, with significant buying and selling activities recorded [1]

Core Viewpoint - The stock of Opcon Vision has shown fluctuations in recent trading days, with a slight increase on September 30, 2023, despite a year-to-date decline of 9.11% [1][2]. Company Overview - Opcon Vision Technology Co., Ltd. was established on October 26, 2000, and went public on January 17, 2017. The company is located in Hefei, Anhui Province, and specializes in the research, production, and sales of optical products and related services [2]. - The main revenue sources for the company include: hard contact lenses (40.86%), other optical products and technical services (21.52%), medical services (19.89%), nursing products (12.57%), non-optical products (4.60%), and other (0.55%) [2]. Financial Performance - For the first half of 2025, Opcon Vision reported a revenue of 871 million yuan, a year-on-year decrease of 1.42%, and a net profit attributable to shareholders of 250 million yuan, down 22.93% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 897 million yuan in dividends, with 526 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Opcon Vision was 61,000, a decrease of 1.56% from the previous period. The average circulating shares per person increased by 1.58% to 10,957 shares [2]. - Major institutional shareholders include Huabao Zhongzheng Medical ETF, Yifangda Growth Enterprise Board ETF, and Southern Zhongzheng 500 ETF, with all showing increases in their holdings compared to the previous period [3].